Skip to main content
Explore URMC


Lymphoma (DLBCL): Impact of CD34+ Cell Dose on Progression-free Survival Following High-Dose Therapy and Autologous Stem Cell Transplantation for Relapsed and Refractory Diffuse Large B-cell Lymphoma (DLBCL)

Research Question:
What is the impact of the stem cell dose (number of cells) on the outcome after autologous transplant?

Basic Study Information

Autologous transplant is the standard treatment for relapsed DLBCL or DLBCL that did not respond to initial chemotherapy. This is a randomized study, a computer program will assign subjects to either the experimental or standard arm. Neither you nor your study doctor will know what group you will be in.

Location: University of Rochester Medical Center
Study Web URL:
Study Reference #: UBMT16009

Lead Researcher (Principal Investigator)

Lead Researcher: Michael Becker, MD

Study Contact Information

Additional Study Details

Learn More About These Conditions

More information about Lymphoma

Return to Search